Shares of Novavax Inc. (NASDAQ:NVAX) traded down 1.6% on Thursday . The stock traded as low as $7.19 and last traded at $7.24, with a volume of 2,778,483 shares changing hands. The stock had previously closed at $7.36.

Several analysts recently weighed in on the stock. Vetr downgraded shares of Novavax from a “strong-buy” rating to a “buy” rating and set a $7.86 price objective on the stock. in a research report on Monday, August 15th. Chardan Capital reiterated a “hold” rating and issued a $5.75 price objective on shares of Novavax in a research report on Sunday, August 14th. FBR & Co set a $17.00 price objective on shares of Novavax and gave the company a “buy” rating in a research report on Thursday, August 11th. Zacks Investment Research downgraded shares of Novavax from a “hold” rating to a “sell” rating in a research report on Wednesday, August 10th. Finally, Citigroup Inc. lifted their price objective on shares of Novavax from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, July 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $11.05.

The company’s market cap is $1.90 billion. The company has a 50 day moving average price of $7.39 and a 200-day moving average price of $5.90.

Novavax (NASDAQ:NVAX) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. The company had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $8.03 million. Novavax’s revenue was down 82.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.08) EPS. Analysts anticipate that Novavax Inc. will post ($1.07) earnings per share for the current fiscal year.

In other Novavax news, Director Gary C. Evans sold 50,000 shares of the business’s stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $5.41, for a total value of $270,500.00. Following the sale, the director now owns 357,111 shares of the company’s stock, valued at approximately $1,931,970.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gary C. Evans sold 18,998 shares of the business’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $6.50, for a total transaction of $123,487.00. Following the completion of the sale, the director now directly owns 321,979 shares in the company, valued at approximately $2,092,863.50. The disclosure for this sale can be found here.

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.